Preliminary estimated total revenue for Q4 2022 of approximately $48 million to $50 million
RAMSEY, NJ & BOCA RATON, Fla., December 6, 2022 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) is an end-to-end commercial biopharmaceutical company . A company dedicated to the manufacture, marketing and development of specialty plasma-derived biologics.
Based on the most recent information available to ADMA’s management, total revenue for the quarter and year ended December 31, 2022 is tentatively estimated to be between $48 million and $50 million to $152 million. Estimated. $154 million each. This projected Q4 2022 revenue represents more than 85% year-over-year growth compared to total Q4 2021 revenue of $26.4 million.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial company dedicated to the manufacture, marketing and development of specialty plasma-derived biologics to treat immunocompromised patients at risk for infection and other patients at risk for certain infectious diseases. A biopharmaceutical company. ADMA currently manufactures and markets his three U.S. Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immunodeficiencies and the prevention of certain infections.® For the treatment of primary humoral immunodeficiency (PI) (intravenous immunoglobulin, human); ASCENIV™ (intravenous immunoglobulin, human – slra 10% liquid) for the treatment of PI; Navi HB® (Hepatitis B immunoglobulin, human) Provides enhanced immunity against the hepatitis B virus. ADMA manufactures its immunoglobulin products at its FDA-approved plasma fractionation and purification facility in Boca Raton, Florida. Through its subsidiary ADMA BioCenters, ADMA also operates as an FDA-approved source plasma collector in the United States, providing a portion of the plasma for the manufacture of its products. ADMA’s mission is to develop specialized plasma products targeted at niche patient populations for the treatment and prevention of specific infectious diseases and for the management of immunocompromised patient populations suffering from or potentially immunocompromised. to manufacture, market and develop human immunoglobulins derived from Weakened immunity for other medical reasons. ADMA holds U.S. Patents 9,107,906, 9,714,283, 9,815,886, 9,969,793, 10,259,865, and European Patent No. 3375789, among others, relating to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995 relating to ADMA Biologics, Inc. (the “Company”, “Our” or “Company”). increase. Forward-looking statements include, but are not limited to, statements that predict, predict, suggest or imply future results, performance or achievements. Also, ‘estimate’, ‘plan’, ‘intention’, ‘forecast’, ‘goal’, ‘expect’, ‘plan’, ‘plan’, ‘expect’, ‘believe’, ‘will’ ‘, ‘likely’, ‘likely’, ‘should’, ‘could’, ‘would’, ‘might’, or in each case the negation thereof, or the like A word or expression with the meaning of These forward-looking statements include statements regarding our estimated fourth quarter and full year 2022 total revenues. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and future security holders are cautioned that there can be no assurance that the forward-looking statements contained in this press release will prove to be accurate. Except to the extent required by applicable law or regulation, ADMA undertakes no obligation to update any forward-looking statement or to announce revisions to any forward-looking statement. Forward-looking statements are subject to a number of risks, uncertainties and other factors that may cause actual results or the timing of certain events to be expressed or implied by the forward-looking statements. may differ significantly from Risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q, and 8-K, and any amendments thereto.
Senior Director of Corporate Strategy and Business Development | 201-478-5552 | email@example.com
Investor Relations Contact:
Managing Director, Argot Partners | 212-600-1902 | firstname.lastname@example.org